by Stacey Hawkins | Apr 21, 2020 | Oncology
Solid tumors are generally considered more difficult to treat than blood cancers. For example, chimeric antigen receptor T-cell (CAR-T) therapy has been amazingly effective against blood cancers that failed to respond to other types of treatment, while inroads against... 
by Stacey Hawkins | Sep 7, 2017 | Immunotherapies
THE FLASH OF THE FIRST CAR-T Last week’s much anticipated FDA approval of the first chimeric antigen receptor T-cell (CAR-T) therapy for acute lymphocytic leukemia hails as the first gene therapy on the US market. Classified as a “cell-based gene therapy,” Novartis’... 
by Stacey Hawkins | Jan 19, 2017 | Immunotherapies
Understanding CAR-T Safety Chimeric antigen receptor therapy (CAR-T) is our top technology pick of 2016, blazing trails in drug development with its innovative approach of using engineered immune cells to fight cancer. Despite its success in clinical trials, safety... 
by Stacey Hawkins | May 26, 2016 | Immunotherapies
The Race Is On Our last WEEKLY—Hacking the Immune Response—unveiled the science behind CAR-T and TCR, two immunotherapies under the microscope of the mainstream press. The well-deserved media attention highlights the ability of these “living drugs” to recognize and... by Stacey Hawkins | Jul 17, 2014 | Uncategorized
DISSOLUTION OF CANCER CLUB WANTED If you are part of the “cancer club,” it means that you are personally familiar with the devastation cancer causes. Far too many of us are members, whether it is through supporting loved ones with cancer or enduring and persevering...
